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5-Hydroxymethylcytosine is an essential
intermediate of active DNA demethylation
processes in primary human monocytes
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Abstract
Background: Cytosine methylation is a frequent epigenetic modification restricting the activity of gene regulatory
elements. Whereas DNA methylation patterns are generally inherited during replication, both embryonic and
somatic differentiation processes require the removal of cytosine methylation at specific gene loci to activate
lineage-restricted elements. However, the exact mechanisms facilitating the erasure of DNA methylation remain
unclear in many cases.
Results: We previously established human post-proliferative monocytes as a model to study active DNA
demethylation. We now show, for several previously identified genomic sites, that the loss of DNA methylation
during the differentiation of primary, post-proliferative human monocytes into dendritic cells is preceded by the
local appearance of 5-hydroxymethylcytosine. Monocytes were found to express the methylcytosine dioxygenase
Ten-Eleven Translocation (TET) 2, which is frequently mutated in myeloid malignancies. The siRNA-mediated
knockdown of this enzyme in primary monocytes prevented active DNA demethylation, suggesting that TET2 is
essential for the proper execution of this process in human monocytes.
Conclusions: The work described here provides definite evidence that TET2-mediated conversion of 5-
methylcytosine to 5-hydroxymethylcytosine initiates targeted, active DNA demethylation in a mature postmitotic
myeloid cell type.
Keywords: Epigenetics, active DNA demethylation, differentiation
Background
DNA methylation is a frequent epigenetic modification
that restricts the activity of regulatory elements, including
cell type-specific gene promoters and enhancers. In mam-
mals, methylated cytosines (5mC) mainly occur in the
context of CpG dinucleotides and the targeted setting and
erasure of the methylation mark is crucial for the silencing
of repetitive and potentially harmful elements and for the
proper execution of essential regulatory programs includ-
ing embryonic development, X-chromosome inactivation,
parental imprinting as well as cellular differentiation [1,2].
While the process of cytosine methylation, which is cata-
lyzed by a group of DNA methyl-transferases (DNMTs) is
well characterized, the exact mechanisms facilitating the
erasure of DNA methylation in mammals remain less
clear and the proposed existence of active enzymatic
demethylation processes has been a matter of controversy
over the last decades [3].
Recent pioneering work has identified the family of Ten-
Eleven-Translocation proteins (TET1-3) that catalyze the
conversion of 5mC to 5-hydroxy-methylcytosine (5hmC)
in mammalian cells [4], and has prompted speculations
that these enzymes are involved in DNA demethylation
processes [5,6]. On the one hand, 5hmC could interfere
with maintenance methylation and induce a passive
demethylation process. On the other hand, TET enzymes
may also initiate active demethylation processes through
repair-associated mechanisms [7].* Correspondence: michael.rehli@klinik.uni-regensburg.de
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Global DNA demethylation is observed during early
embryonal development in particular in zygotes and pri-
mordial germ cells and 5hmC has been detected in both
pathways [8,9]. The initial massive erasure of 5mC in pri-
mordial germ cells, however, appears to be a TET-indepen-
dent, passive process that is likely controlled by the
downregulation of UHRF1, which facilitates the recruit-
ment of the maintenance DNA-methyltransferase DNMT1
to nascent hemimethylated DNA at the replication fork
[10]. In the zygote, however, TET3 mediated conversion of
5mC to 5hmC is essential for the reprogramming of the
zygotic paternal DNA after fertilization [11-13]. 5hmC is
then gradually replaced by unmethylated cytosines during
preimplantation development, suggesting that the erasure
of 5hmC in zygotes is also a DNA replication-dependent
passive process [12].
Another member of this family (TET2) directly affects
myelopoiesis and diverse myeloid malignancies (includ-
ing myelodysplastic syndromes, chronic myelomonocytic
leukemia, myeloproliferative neoplasms, and acute mye-
loid leukemia) are frequently associated with mutations
in this gene [14-16]. Targeted disruption or knockdown
of TET2 results in reduced levels of 5hmC and affects
self-renewal and differentiation of hematopoietic stem
cells [17-20]. However, the exact mechanisms that contri-
bute to disease pathology are currently unknown.
Here we provide direct evidence that the TET2-depen-
dent conversion of 5mC to 5hmC is required for active
DNA demethylation in primary human monocytes. Similar
processes are likely to occur in other myeloid (progenitor)
cells and the reduced ability to erase DNA methylation
at critical regulatory sites in cases with TET2 loss-of-
function mutations may therefore contribute to disease
pathology.
Results and discussion
Many previous studies focused on proliferating cell types
that were mitotically arrested to distinguish between active
and passive DNA demethylation mechanisms. Using
methyl-CpG-immunoprecipitation (MCIp) and a global
microarray-based approach to detect differences in DNA
methylation [21,22], we recently identified a number of
actively demethylated regions in a natural setting of post-
mitotic cells: the differentiation of human peripheral blood
monocytes into monocyte-derived macrophages or dendri-
tic cells (Figure 1). DNA demethylation events were highly
reproducible and paralleled or followed the appearance of
‘activating’ histone modifications, suggesting that a pro-
posed DNA demethylation machinery is recruited as part
of other chromatin-modifying processes associated with
gene activation or transcriptional priming [23]. However,
the exact mechanisms leading to DNA demethylation in
human monocytes remain unclear.
Recent studies have implicated the family of Ten-Ele-
ven-Translocation proteins (TET1-3) in active demethy-
lation processes via the generation of 5hmC. To test
whether TET proteins might be involved, we studied the
appearance of 5hmC at previously defined sites of active
DNA demethylation [23] in time-courses of differentiat-
ing human monocytes and compared the appearance of
5hmC (measured using hMeDIP) with traditional mea-
surements of bisulfite treated DNA (which globally con-
verts cytosines to uracil except 5mC and 5hmC) using
mass spectrometry as well as 5mC levels measured by
MeDIP. Figure 2 summarizes the results for six different
genomic regions. These loci (schematically illustrated in
Figure 2A) included four regions showing DNA
demethylation with either fast (CCL13, USP20) or slow
kinetics as well as two control regions characterized by
constitutive DNA methylation (HOXB1) or demethyla-
tion (MMP7) during the time courses. As shown in Fig-
ure 2C, the local erasure of DNA methylation (5mC and
5hmC as detected by mass spectrometry) was always
found to correlate with the synchronous appearance of
5hmC (as measured by hMeDIP). At the CCL13 promo-
ter both 5mC and 5hmC disappeared at later stages of
DC differentiation, suggesting that the erasure of methy-
lation marks might proceed to completeness (as
observed at CpG dinucleotide 1) in this case. Since mea-
surements of bisulfite treated DNA do not distinguish
between 5mC and 5hmC, we also followed local DNA
methylation levels using MeDIP (Figure S1 in Additional
File 5). While the 5mC antibody appeared less sensitive
compared to the 5hmC antibody, we also observed
demethylation of the four loci using this method. The
local conversion of 5mC to 5hmC was further confirmed
by an independent approach utilizing 5hmC-specific
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Figure 1 Monocyte differentiation in vitro. Schematic presentation
of the postmitotic differentiation model of in vitro monocyte
differentiation. Monocytes do not proliferate (as demonstrated by the
lack of nucleotide incorporation) and DNA demethylation therefore
requires an active process.
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glycosyltransferase for 5hmC detection by glycosylation-
sensitive restriction (Figure S2 in Additional File 5). These
results clearly established that 5hmC appears at actively
demethylated sites during monocyte differentiation.
To study a causal relationship between TET2 enzymes
and DNA demethylation, we analyzed mRNA expression
of TET genes during monocyte differentiation and found
that monocytes and monocyte-derived cells primarily
expressed TET2 (Figure 3). Expression of TET1 was
undetectable and expression of TET3 was much weaker
and less reproducible (Figure 3). In contrast to TET2 (see
below) we were also unable to detect TET1 or TET3 by
western blotting using commercial antibodies. These data
established TET2 as the candidate enzyme for the local
oxidation of 5mC in monocytes.
To test whether ablation of TET2 would affect the
process of active DNA demethylation, we established a
transient siRNA transfection protocol for freshly isolated
human blood monocytes using control- or TET2-siRNA
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Figure 2 5hmC deposition precedes active DNA demethylation in human monocytes. (A) Positions of regions (purple) measured by
MALDI-TOF analysis of bisulfite converted DNA (MassARRAY, in B) and of primers (red) used for hMeDIP qPCR (in C) are shown relative to
positions of CpG dinucleotides (green) and neighboring genes (blue). Tracks were generated using the UCSC Genome Browser. (B) MassARRAY
analysis of bisulfite-converted DNA at four loci that show active DNA demethylation during monocyte to DC differentiation, as well as for two
control regions (values are mean of n≥4). Data are presented as heatmaps. The methylation content (including both 5mC and 5hmC) is
indicated by coloring (yellow: no methylation, dark blue: 100% methylation) with each box representing a single CpG dinucleotide and each row
representing the succession of CpGs measured. Grey boxes indicate CpGs that were not detected by MALDI-TOF MS. Red asterisks mark the
CpGs that are shown in (C). Methylation ratios of single CpG units for individual donors are also provided in Table S2 in Additional File 2. (C)
Dynamics of DNA methylation (5mC + 5hmC) and hydroxymethylation (5hmC) during monocytic differentiation. DNA methylation levels of
single CpGs as measured by MassARRAY (open squares) are compared with 5hmC enrichment (measured by hMeDIP, red squares) at the same
loci shown in (B) (n≥4, values are mean + or - SD). Exact genomic positions of analyzed CpG residues are given in Table S3 in Additional File 3.
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Figure 3 TET2 is expressed in human monocytes. The expression
profile of TET2 during monocyte differentiation into dendritic cells is
shown. Quantitative RT-PCR results are shown relative to HPRT1
expression and represent mean values ± SD (n=6). TET3 levels were
considerably lower and no mRNA expression was detected for TET1
in monocytes or monocyte-derived cells.
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before culturing them under iDC culture conditions.
Monocytes are generally difficult to transfect - as sensi-
tive sentinels of the innate immune system, they
respond to foreign nucleic acids including plasmid DNA
and siRNAs, which affects differentiation and survival.
We thus only studied ‘early’ time points (27 h and 42 h)
after transfection where survival was largely unaffected
by siRNA transfection (Figure S3A in Additional File 5).
As shown by the reduced expression of the DC markers
CD1a (FACS staining in Figure S3A and qRT-PCR in
Figure S3B in Additional File 5) and CCL13 (qRT-PCR
in Figure S3B in Additional File 5) the transfection did
have an effect on the differentiation process. Concomi-
tant, transient transfections also delayed DNA demethy-
lation (see below), but since the process was clearly
detected, the siRNA approach still allows addressing the
demethylation mechanism. In addition to analyzing the
effects of TET2 knockdown, we also established the
siRNA-mediated knockdown of the two DNA glycosy-
lases MBD4 and TDG that have previously been impli-
cated in the removal of deaminated 5mC [7,24,25] or
5hmC via 5-Carboxylcytosine (5caC) [26,27] in other
cellular systems. As shown in Figure 4A-C the average
knockdown at 27 h or 42 h ranged between 25% and
60% and 5% and 40% of control siRNA transfected cells
on RNA and on protein level, respectively.
To study the effect of siRNA knockdowns, DNA methy-
lation levels were analyzed at 27 h or 42 h using mass spec-
trometry of bisulfite treated DNA. Results are shown as
heatmaps for the entire regions (Figure 4D) and bar charts
for selected individual CpGs (Figure 4E). Interestingly, the
methylation pattern derived from bisulfite treated DNA
after knockdown of MBD4 or TDG was undistinguishable
from control siRNA treatment (Figure 4D and 4E). This
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Figure 4 TET2 is required for active DNA demethylation in human monocytes. (A-C) mRNA (left panels) and protein expression (right panels) of
TET2, MBD4, or TDG in monocytes left untreated or transfected with the corresponding TET2-, MBD4-, TDG-siRNA, or control siRNA after 27 h and 42 h
of differentiation culture. qRT-PCR results were normalized to HPRT1 expression (n≥4, values are mean ± SD, * P <0.05 Student’s T-test, paired, two-
sided). Protein levels of TET2, MBD4, or TDG were analysed using western blotting (results are representative of n=3 independent experiments).
(D) MassARRAY analysis of bisulfite-converted DNA at five loci that show active DNA demethylation during monocyte to DC differentiation, as well as
for two control regions (values are mean of n≥4). Data are presented as heatmaps. The methylation content (including both 5mC and 5hmC) is
indicated by coloring (yellow: no methylation, dark blue: 100% methylation) with each box representing a single CpG dinucleotide and each row
representing the succession of CpGs measured. Grey boxes indicate CpGs that were not detected by MassARRAY. Asterisks mark the CpGs that are
shown in (E). Red arrows mark TET2-siRNA treated samples that show a specific decrease in demethylation. (DNase1L3 methylation did not change
during the first 42 h, but spectra were of low quality and are not shown.) Methylation ratios of single CpG units for individual donors are also provided
in Table S4 in Additional File 4. (E) Bar charts for MassARRAY results of the indicated CpG residues of actively demethylated (CCL13, USP20) or control
loci (MMP7, HOXB1). Values are mean ± SD (n≥4; * P <0.05, *** P <0.001 Student’s T-test, paired, two-sided).
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indicates that neither of these two enzymes actively con-
verts 5hmC, which is in line with previous observations
[27]. Tet proteins were recently shown to metabolize
5hmC to 5-formylcytosine (5fC) and 5caC [28], which are
both converted into uracil during bisulfite treatment
[26,29]. Because we cannot distinguish 5fC/5caC from
unmethylated cytosine residues after bisulfite treatment,
we are currently not able to address whether MBD4 or
TDG are active to ‘complete’ the demethylation process in
primary monocytes that is initiated by TET2 mediated pro-
cessing of 5mC into 5hmC and further into 5fC/5caC.
Since human blood monocytes are (in contrast to mono-
cyte-derived macrophages or dendritic cells) severely
impaired in base and DNA double-strand break repair [30],
the exchange of the two 5mC derivatives may be delayed.
To test whether 5fC/5caC accumulate as the end product
of the demethylation process at the CCL13 promoter, we
analyzed the restriction efficiency of MspI (which is inhib-
ited by the presence of 5caC or 5fC [28]) at the site cover-
ing one of the demethylated CpGs. While MspI can also be
inhibited by methylation of the outer C (5mCCGG) and
thus may not allow the quantification of 5caC or 5fC, the
fact that DNA from iDC (as well as from all knockdown
experiments) could be efficiently cut with this restriction
enzyme (Figure S4 in Additional File 5) suggests that the
demethylation process is completed (5mC®5C) in iDC.
MBD4 or TDG knockdown did not lead to a decrease in
restriction efficiency, indicating that 5caC or 5fC do not
accumulate at these sites in transfected monocytes. It is
thus still unclear whether TDG, MBD4, or another enzyme
initiates the last steps of the active demethylation process.
Notably, a recent mass spectrometry study systematically
identified readers in embryonic stem cells, neuronal pro-
genitor cells, and brain for all known 5C derivates [31].
This study identified a number of additional DNA glycosy-
lases (Neil1, Neil3), as well as helicases (Hells, Harp, Recql,
and its homolog Bloom) binding specifically to hmC sug-
gesting that this derivate may already attract DNA-repair
enzymes and perhaps initiate DNA demethylation in differ-
entiating monocytes.
The TET2-siRNA treatment, however, resulted in signifi-
cantly different methylation patterns: the local loss of DNA
methylation at the two loci showing rapid 5mC erasure
(CCL13 and USP20) was significantly delayed in cells with
reduced TET2 expression (Figure 4D and 4E), while control
regions were unaffected and the late demethylation targets
did not show any signs of methylation loss at these early
time points. We also analyzed local 5hmC levels using hMe-
DIP (Figure S5A in Additional File 5), as well as glycosyla-
tion-sensitive restriction (Figure S5B in Additional File 5)
and detected a significant reduction of 5hmC at demethy-
lated regions only in TET2-siRNA-treated monocytes.
These results clearly establish that differentiating monocytes
require TET2 to initiate the active demethylation process.
As shown previously, DNA demethylation in primary
monocytes is characterized by the parallel appearance of
activating histone marks, such as mono- and dimethyla-
tion of H3K4 or acetylation of histones H3 and H4 [23],
which are typical features of enhancers. This is also in
line with the recent observation of dynamic deposition
of 5hmC at differentiation-associated enhancers in other
cellular systems [32]. The histone modifications likely
follow the recruitment of DNA-binding factors that
direct histone methyl- and/or acetyl-transferases to
these sites [23]. The local appearance of 5hmC suggests
that the modified histones or the same factors responsi-
ble for the modification of histones may also recruit the
5-methylcytosine dioxygenase TET2 to initiate DNA
demethylation of newly activated and/or remodeled
sites.
Conclusions
Our data unequivocally show that the TET2-mediated
conversion of 5mC to 5hmC is an essential intermediate
in targeted, locus-specific active demethylation processes
that are observed during the differentiation of non-divid-
ing human monocytes. This function of TET2 may also
be essential for the differentiation of earlier myeloid pro-
genitor stages, as a significant proportion of myeloid dys-
plasia are characterized by loss-of-function mutations of
TET2.
Materials and methods
Cells
Collection of blood cells from healthy donors was per-
formed in compliance with the Helsinki Declaration.
All donors signed an informed consent. The leuka-
pheresis procedure, the subsequent purification of
peripheral blood monocytes by density gradient centri-
fugation over Ficoll/Hypaque as well as the counter
current centrifugal elutriation were approved by the
local ethical committee (reference number 92-1782
and 09/066c). The generation of monocyte-derived
dendritic cells and macrophages has been described
previously [23].
DNA isolation
Genomic DNA was prepared using the DNeasy Blood
and Tissue Kit from Qiagen (Hilden, Germany).
Mass spectrometry analysis of bisulfite-converted DNA
Sodium bisulfite conversion and quantitative analysis of
DNA methylation using MALDI-TOF mass spectrometry
(MassARRAY Compact MALDI-TOF, Sequenom, San
Diego, CA, USA) was performed as described [23,33].
Primers for amplicon generation were described [23] or
are listed in Table S1 in Additional File 1.
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hMeDIP & MeDIP
Enrichment of 5- methylcytosine (5mC) or 5-hydroxy-
methylcytosine (5hmC) was analyzed by immunoprecipita-
tion using 5-methylcytidine and 5-hydroxy-methylcytidine
antibodies (Diagenode and Active Motif, respectively)
essentially as described for 5mC in Mohn et al. [34].
Enriched DNA was purified with the PCR purification kit
from Qiagen and quantified on a Realplex Mastercycler
EP (Eppendorf, Hamburg, Germany) using the Quantifast
SYBR Green PCR Kit (Qiagen) as indicated by the manu-
facturer. Primer sequences were previously described or
are listed in Table S1 in Additional File 1.
Glycosylation of 5hmC
Site-specific detection of 5hmC by glycosylation was done
using the Quest 5-hmC detection kit (Zymo Research) fol-
lowing the manufacturer’s instructions with modifications.
After the glycosylation step (prolonged to 3 h), samples
were cleaned using the DNA clean and concentrator kit
(Zymo) and subsequently digested with 30 U MspI (NEB),
or 30 U HpaII (NEB) at 37°C overnight. The fraction of
glycosylated and therefore protected MspI sites as well as
the fraction of 5mC- and 5hmC-sensitive sites (determined
using HpaII restriction) at specific gene loci were quanti-
fied by qPCR using primers described in [23] or primers
listed in Table S1 in Additional File 1.
Quantitative RT-PCR
Total cellular RNA was isolated using the RNeasy Mini Kit
(Qiagen) and reverse transcribed using Superscript II
MMLV-RT (Promega, Mannheim, Germany). Real-time
PCR was performed on a Realplex Mastercycler EP
(Eppendorf, Hamburg, Germany) as described above.
Primer sequences are listed in Table S1 in Additional
File 1.
Transfection of primary human monocytes
Peripheral blood monocytes were transfected using the
Human Monocyte Nucleofector Kit from Lonza (Cologne,
Germany). In brief, 6×106 cells were resuspended in 100
μL Nucleofector solution (Lonza) with 600 nM TET2-,
MBD4-, TDG-, or control-siRNA (all from Thermo Scien-
tific Dharmacon) and electroporated using the Nucleofec-
tor I device. Cells were cultured as described without the
addition of antibiotics. Expression of targeted genes as
well as DNA methylation was measured after 27 h or 42 h
in culture.
Western blotting
To follow knockdown efficiency on protein level, cells
were harvested 27 h and 42 h after transfection, washed
with PBS and lysed in 2x SDS-Lysis Buffer (20%
Glycerin, 125mM Tris pH 6.8, 4% SDS, 10% 2-Mercap-
toethanol, 0.02% Bromophenolblue). Lysates were boiled
(95°C, 10 min) and 1.5 × 105 to 5 × 105 cells per lane
separated on 8% or 10% polyacrylamide gels (Biometra
Minigel Gelelectrophoresis device). Proteins were trans-
ferred to nitrocellulose membranes (Live Technologies,
0.45 μM pore size) using the Biometra Fastblot semi-dry
blotter or the Biorad Mini Transblot Cell wet system
according to the protein size. After 1 h of blocking in
TBS-T with 5% dry milk at room temperature the mem-
branes were incubated with either Anti-TET2 (1:2,000, a
gift from O. Bernard), Anti-TDG (1:10,000, a gift from
Primo Schär), Anti-MBD4 (1:2,000, from Diagenode) or
Anti-actin (Sigma Aldrich) overnight at 4°C. Second anti-
body (Dako, Glostrup, Denmark) incubation was carried
out at room temperature for 1 h. Flourescence signals
were detected after exposure to ECL hyperfilm or using a
fluorescence scanner (BioRad, Chemi Doc XRS+).
Quantification of MspI restriction efficiency
DNA from monocyte-derived dendritic cells (iDC, 100ng)
was digested with MspI plus HhaI or with HhaI alone (20
U each, New England BioLabs) overnight (approximately
16 h) at 37°C. The efficiency of MspI cutting was mea-
sured by comparing the qPCR amplification of DNA
fragments across the MspI site in MspI-digested and
-undigested DNA samples.
Additional material
Additional file 1: Table S1. Word DocumentTitle of this dataset: Table
S1, Oligonucleotide sequences used for PCRDescription of this dataset:
Table S1 lists sequences of oligonucleotides for various PCR-based
analyses.
Additional File 2: Table S2. Excel FileTitle of this dataset: Table S2,
EpiTYPER resultsDescription of this dataset: Table S2 lists MassARRAY
EpiTYPER results. EpiTYPER methylation ratios of individual CpG units in
12 amplicons covering six distinct genomic locations are given for all
knockdown samples of different donors.
Additional file 3: Table S3. Excel FileTitle of this dataset: Table S2,
EpiTYPER resultsDescription of this dataset: Table S2 lists MassARRAY
EpiTYPER results. EpiTYPER methylation ratios of individual CpG units in
12 amplicons covering six distinct genomic locations are given for all
time course samples of different donors.
Additional file 4: Table S4. Word DocumentTitle of this dataset: Table
S2, Genomic position of analyzed CpG residuesDescription of this
dataset: Table S2 lists genomic positions of CpG residues that were
analyzed by MassARRAY or QUEST-qPCR.
Additional file 5: Supplementary Figures. PDFTitle of this dataset:
Supplementary FiguresDescription of this dataset: Contains
supplementary figures S1-5.
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5caC: 5-carboxylcytosine; 5fC: 5-formylcytosine; 5hmC: 5-
hydroxymethylcytosine; 5mC: 5-methylcytosine; BrdU: 5-Bromo-2’-deoxy-
uridine; iDC: immature dendritic cell; MO: monocyte; MAC: macrophage
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